Skip to content

Microdosing: all studies

Page 19 of 56: studies 181 to 190 of 555, newest first. Back to the microdosing overview

Research

Microdosing: Knowledge Distillation for GAN based Compression

arXiv Preprint Archive January 7, 2022 Leonhard Helminger, Roberto Azevedo, Abdelaziz Djelouah et al. preprint

Recently, significant progress has been made in learned image and video compression. In particular the usage of Generative Adversarial Networks has lead to impressive results in the low bit rate regime. However, the model size remains an important issue in current state-of-the-art proposals and existing solutions require significant computation effort on the decoding side. This limits their...

Buprenorphine Microdosing for the Pain and Palliative Care Clinician

Journal of Palliative Medicine December 20, 2021 Kyle Quirk, Maximillian H. Stevenson

Buprenorphine (BUP) can be a safe and effective alternative to traditional opioids for many patients with chronic pain. For patients on higher doses of opioids, rotation to BUP is complicated by the requirement of an opioid-free interval or withdrawal during the transition. Microdosing inductions, in which BUP is gradually titrated, while full agonist opioids are continued, are a viable...

Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study

Journal of Psychopharmacology December 17, 2021 Josephine Marschall, George Fejer, Pascal Lempe et al. 69 citations

Background: Microdoses of psychedelics (i.e. a sub-hallucinogenic dose taken every third day) can reduce symptoms of depression, anxiety and stress according to anecdotal reports and observational studies. Research with medium to high doses of psilocybin points towards potential underlying mechanisms, including the modulation of emotion and interoceptive processing. Aims: In this preregistered...

The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955 – 2021)

December 15, 2021 Vince Polito, Paul Liknaitzky 2 citations preprint

The use of low doses of psychedelic substances (microdosing) is attracting increasing interest. This systematic review summarises all empirical microdosing research to date, including a set of infrequently cited studies that took place prior to prohibition. Specifically, we reviewed 44 studies published between 1955 and 2021, and summarised reported effects across six categories: mood and...

DOI: 10.31234/osf.io/edhqz (opens in new tab) Full text (opens in new tab) Expectancy theory Mood Cognition Perception +4

Microevidence for microdosing with psilocybin mushrooms: a double-blind placebo-controlled study of subjective effects, behavior, creativity, perception, cognition, and brain activity

bioRxiv (Cold Spring Harbor Laboratory) December 7, 2021 Federico Cavanna, Stephanie Müller, Laura Alethia de la Fuente et al. 8 citations preprint

Abstract The use of low sub-hallucinogenic doses of psychedelics (“microdosing”) has gained popularity in recent years. Although anecdotal reports claim multiple benefits associated with this practice, the lack of placebo-controlled studies limits our knowledge of microdosing and its effects. Moreover, research conducted in laboratory settings might fail to capture the motivation of individuals...

Microdosing of Psychoactive Substances in Business Practice

Businesses December 6, 2021 Karel Lehmert, Eva Ambrozova, Vratislav Pokorný et al. 3 citations

Abusing psychoactive substances has been a popular sport in the business world since the mid-19th century. First, they were appreciated for their stimulating or tonic effects, but later with psychedelics on the scene, their importance in subculture matured. In the last decade, it has become very popular to use LSD and cocaine in subtle doses, which provides users with a high that is enough to...

DOI: 10.3390/businesses1030014 (opens in new tab) Dosing Drugs of abuse Pharmacology

No evidence that LSD microdosing affects recall or the balance between distracter resistance and updating

bioRxiv Preprint Server December 2, 2021 Sean James Fallon 2 citations preprint

The effect of low doses (<=20 μg) of LSD on working memory, in the absence of altered states of consciousness, remain largely unexplored. Given its possible effects on serotonin 5-HT2A receptors and dopaminergic signalling, it could be hypothesised that LSD microdoses modulate working memory recall. Moreover, in line with computational models, LSD microdoses could exert antagonistic effects on...

DOI: 10.1101/2021.12.02.470935 (opens in new tab) Full text (opens in new tab) Small Doses LSD Low Doses LSD Psychedelic microdosing Psychedelics +12

Radiolabeling and PET–MRI microdosing of the experimental cancer therapeutic, MN-anti-miR10b, demonstrates delivery to metastatic lesions in a murine model of metastatic breast cancer

Cancer Nanotechnology July 11, 2021 Mariane Le Fur, Alana Ross, Pamela Pantazopoulos et al.

Abstract Background In our earlier work, we identified microRNA-10b (miR10b) as a master regulator of the viability of metastatic tumor cells. This knowledge allowed us to design a miR10b-targeted therapeutic consisting of an anti-miR10b antagomir conjugated to ultrasmall iron oxide nanoparticles (MN), termed MN-anti-miR10b. In mouse models of breast cancer, we demonstrated that MN-anti-miR10b...

DOI: 10.1186/s12645-021-00089-5 (opens in new tab) Full text (opens in new tab) Microrna Rna interference Metastasis Biodistribution +2

Abstract 1311: PET-MRI microdosing can determine the delivery of the experimental cancer therapeutic, MN-anti-miR10b, to metastatic lesions in a murine model of breast cancer

Cancer Research July 1, 2021 Marianne Le Fur, Byunghee Yoo, Nicholas Rotile et al.

Abstract: Conventional therapies, which are effective against primary cancer, oftentimes are not successful at treating metastatic cancer. In our earlier work, we identified miRNA-10b as a master regulator of the viability of metastatic tumor cells. This knowledge allowed us to design a miR-10b inhibitor, termed MN-anti-miR10b, capable of delivery to metastatic sites via intravenous injection....

Microdosing psychedelics and its effect on creativity: Lessons learned from three double-blind placebo controlled longitudinal trials

June 14, 2021 Luisa Prochazkova, Michiel van Elk, Josephine Marschall et al. 4 citations preprint

Introduction: Microdosing refers to the repetitive administration of tiny doses of psychedelics (LSD, Psilocybin) over an extended period of time. This practice has been linked to alleged cognitive benefits, such as improved mood and creativity, potentiated by targeting serotonergic 5-HT2A receptors and facilitating cognitive flexibility. Nonetheless, in the absence of robust, quantitative and...